Skip to main content

Thank you for visiting nature.com. You are using a browser version with limited support for CSS. To obtain the best experience, we recommend you use a more up to date browser (or turn off compatibility mode in Internet Explorer). In the meantime, to ensure continued support, we are displaying the site without styles and JavaScript.

  • Correspondence
  • Published:

Diet and depression: future needs to unlock the potential

This is a preview of subscription content, access via your institution

Access options

Buy this article

Prices may be subject to local taxes which are calculated during checkout

References

  1. Jacka FN, O’Neil A, Itsiopoulos C, Opie R, Cotton S, Mohebbi M, et al. The SMILES trial: an important first step. BMC Med. 2018;16:1–3.

    Article  Google Scholar 

  2. Nicolaou M, Colpo M, Vermeulen E, Elstgeest LE, Cabout M, Gibson-Smith D, et al. Association of a priori dietary patterns with depressive symptoms: a harmonised meta-analysis of observational studies. Psychol Med. 2020;50:1872–83.

    Article  Google Scholar 

  3. Firth J, Marx W, Dash S, Carney R, Teasdale SB, Solmi M, et al. The effects of dietary improvement on symptoms of depression and anxiety: a meta-analysis of randomized controlled trials. Psychosom Med. 2019;81:265.

    Article  Google Scholar 

  4. Jacka FN, O’Neil A, Opie R, Itsiopoulos C, Cotton S, Mohebbi M, et al. A randomised controlled trial of dietary improvement for adults with major depression (the ‘SMILES’trial). BMC Med. 2017;15:1–13.

    Article  Google Scholar 

  5. Parletta N, Zarnowiecki D, Cho J, Wilson A, Bogomolova S, Villani A, et al. A Mediterranean-style dietary intervention supplemented with fish oil improves diet quality and mental health in people with depression: a randomized controlled trial (HELFIMED). Nutritional Neurosci. 2019;22:474–87.

    Article  CAS  Google Scholar 

  6. Francis HM, Stevenson RJ, Chambers JR, Gupta D, Newey B, Lim CK. A brief diet intervention can reduce symptoms of depression in young adults–a randomised controlled trial. PLoS ONE. 2019;14:e0222768.

    Article  CAS  Google Scholar 

  7. Chatterton ML, Mihalopoulos C, O’Neil A, Itsiopoulos C, Opie R, Castle D, et al. Economic evaluation of a dietary intervention for adults with major depression (the “SMILES” trial). BMC Public Health. 2018;18:1–11.

    Article  Google Scholar 

  8. Bot M, Brouwer IA, Roca M, Kohls E, Penninx BW, Watkins E, et al. Effect of multinutrient supplementation and food-related behavioral activation therapy on prevention of major depressive disorder among overweight or obese adults with subsyndromal depressive symptoms: the MooDFOOD randomized clinical trial. JAMA. 2019;321:858–68.

    Article  CAS  Google Scholar 

  9. Vreijling SR, Penninx BW, Bot M, Watkins E, Owens M, Kohls E et al. Effects of dietary interventions on depressive symptom profiles: results from the MooDFOOD depression prevention study. Psychol Med 2021;7:1–10.

  10. Reynolds CF III, Thomas SB, Morse JQ, Anderson SJ, Albert S, Dew MA, et al. Early intervention to preempt major depression among older black and white adults. Psychiatr Serv. 2014;65:765–73.

    Article  Google Scholar 

  11. Jacka FN. Nutritional psychiatry: where to next? EBioMedicine. 2017;17:24–29.

    Article  Google Scholar 

  12. Malhi GS, Bell E, Bassett D, Boyce P, Bryant R, Hazell P, et al. The 2020 Royal Australian and New Zealand College of Psychiatrists clinical practice guidelines for mood disorders. Aust N Z J Psychiatry. 2021;55:7–117.

    Article  Google Scholar 

Download references

Funding

WM is currently funded by an Alfred Deakin Postdoctoral Research Fellowship and a Multiple Sclerosis Research Australia early-career fellowship. WM has previously received funding from the Cancer Council Queensland and university grants/fellowships from La Trobe University, Deakin University, University of Queensland, and Bond University. WM has received industry funding and has attended events funded by Cobram Estate Pty. Ltd. WM has received travel funding from Nutrition Society of Australia, has received consultancy funding from Nutrition Research Australia and ParachuteBH, and has received speakers honoraria from The Cancer Council Queensland and the Princess Alexandra Research Foundation. MML is funded by a Deakin University PhD Scholarship and has received research support from BeFit Foods. MH is supported by an Australian Rotary Health PhD Scholarship and has received research support from The A2 Milk Company. HA is supported by a Deakin University Dean’s Postdoctoral Research Fellowship. KW has previously received funding from Australian Research Council, National Health and Medical Research Council, and ChemGenex Pharmaceuticals. AB and CMP have received research funding from Johnson & Johnson for research on depression and inflammation, which included cellular work (2012–2018); moreover, CMP is funded by a Wellcome Trust strategy award to the Neuroimmunology of Mood Disorders and Alzheimer’s Disease (NIMA) Consortium (104025), which is also funded by Janssen, GlaxoSmithKline, Lundbeck and Pfizer. The work presented in this paper is unrelated to this funding. AB and CMP are funded by the UK Medical Research Council (grants MR/L014815/1, MR/J002739/1 and MR/N029488/1), the European Commission Horizon 2020 (grant SC1-BHC-01-2019) and the National Institute for Health Research (NIHR) Biomedical Research Centre at South London and Maudsley NHS Foundation Trust and King’s College London. CMP is an NIHR Senior Investigator (2017-2025). KB is funded by an Irish Research Council postdoctoral fellowship and has received speakers honoraria from Yakult. JFC is supported by Science Foundation Ireland in the form of a Research Centre grant (SFI/12/RC/2273-P2), Joint Programming Initiative JPI-HDHL-NutriCog project ‘AMBROSIAC’ (15/JPHDHL/3270); Joint Programming Initiative HEALTHMARK: Metabolic HEALTH through nutrition, microbiota and tryptophan bioMARKers,” 16/ERAHDHL/3362. (EU Horizon 2020 funding–DISCOvERIE (Development, dIagnosis and prevention of gender-related Somatic and mental COmorbiditiEs in iRrItable bowel syndrome in Europe), Swiss National Foundation Sinergia grant GUT-BRAIN; Irish Research Council; European Union’s Horizon 2020 research and innovation programme under the Marie Skłodowska-Curie grant agreement number 797592 and 754535; Irish Research Council Postgraduate Scholarship GOIPG/2019/3198; GOIPG/2018/2560; Health Research Board (HRB) Grant number ILP-POR-2017-013; Institute for Scientific Information on Coffee and the Saks Kavanaugh Foundation. JFC received research support from Mead Johnson, Cremo, 4D Pharma, Pharmavite and Nutricia. He has been a consultant for Alkermes and Nestle, and has spoken at meetings sponsored by Mead Johnson, Abbott Nutrition, Roche, Ordesa and Neuraxpharm. GC is a funded investigator in APC Microbiome Ireland, a research centre funded by Science Foundation Ireland (SFI) (grant number 12/RC/2273). His research is currently supported by the Irish Health Research Board (HRB) (Grant number ILP-POR-2017-013). GC has received honoraria from Janssen, Probi and Apsen as an invited speaker, is in receipt of research funding from Pharmavite and Fonterra, and is a paid consultant for Yakult and Zentiva. J Firth is supported by a University of Manchester Presidential Fellowship (P123958) and a UK Research and Innovation Future Leaders Fellowship (MR/T021780/1), and has received honoraria/consultancy fees from Atheneum, ParachuteBH and Nirakara, independent of this work. JMC is currently funded by the Australian Research Council (DP190103081); the National Health and Medical Research Council (APP114333; APP1079102); the Waterloo Foundation; DNA Genotek; and Trajan Scientific and Medical. K-PS has received the following research grants related to this work: MOST109-2320-B-038-057-MY3, 109-2320-B-039-066, 110-2321-B-006-004, 110-2811-B-039-507, 110-2320-B-039-048-MY2 and 110-2320-B-039-047-MY3 from the Ministry of Science and Technology, Taiwan; CMRC-CMA-2 from Higher Education Sprout Project by the Ministry of Education (MOE), Taiwan; CMU108-SR-106 from the China Medical University, Taichung, Taiwan; and CRS-108-048 and ANHRF109-31, 110-13 and 110-26 from An Nan Hospital, China Medical University, Tainan, Taiwan. K-PS has been a speaker and/or consultant for Johnson & Johnson, AstraZeneca, Lundbeck, Eli Lilly, Merck, Pfizer, Servier, Otsuka, Excelsior Biopharma, Chen Hua Biotech, Nutrarex Biotech and Hoan Pharmaceuticals—all unrelated to this work. DM has received research support from Nordic Naturals and heckel medizintechnik GmbH. He has provided unpaid consulting for Pharmavite LLC and Gnosis USA, Inc. He has received honoraria for speaking from the Massachusetts General Hospital Psychiatry Academy, Blackmores, Harvard Blog and PeerPoint Medical Education Institute, LLC. He has received royalties from Lippincott Williams and Wilkins for published book ‘Natural medications for Psychiatric Disorders: considering the Alternatives’. He also works with the MGH Clinical Trials Network and Institute (CTNI), which has received research funding from multiple pharmaceutical companies and NIMH. FG-P is currently funded by research awards from the NINDS of National Institute of Health. He serves as a consultant and member of the Scientific Advisory Board of Nutrient Foods, LLC. J Foster received research funding from the National Sciences and Engineering Research Council of Canada (NSERC), and the Ontario Brain Institute, which is an independent non-profit corporation, funded partially by the Ontario Government. J Foster has received consultancy fees from Novozymes A/S and Rothmans, Benson & Hedges, Inc. PDC is a senior research associate at FRS-FNRS (Fonds de la Recherche Scientifique), Belgium. He is supported by the Fonds Baillet Latour (Grant for Medical Research 2015), the Fonds de la Recherche Scientifique (FNRS, FRFS-WELBIO: WELBIO-CR-2019C-02R) and ERC Starting Grant 2013 (336452-ENIGMO). PDC is the co-founder of A-Mansia Biotech SA and inventors on patent applications about the therapeutic use of Akkermansia muciniphila and its components. Diet and mental health research in the Thuret lab is funded by grants awarded by the Medical Research Council UK (MR/N030087/1 and MR/S00484X/1, the European Union’s H2020 Joint Programming Initiative ‘A Healthy Diet for a Healthy Life’ and the Network of Centres of Excellence in Neurodegeneration (COEN). HS has previously received non-financial and financial support from CD investments VSL pharmaceuticals and is currently funded by an Alfred Deakin Postdoctoral Research Fellowship. AO’N is supported by a Future Leader Fellowship (#101160) from the Heart Foundation Australia and Wilson Foundation. She has received research funding from the National Health & Medical Research Council, Australian Research Council, University of Melbourne, Deakin University, Sanofi, Meat and Livestock Australia and Woolworths Limited, and Honoraria from Novartis. The Food & Mood Centre has received funding from the Fernwood Foundation, the A2 Milk Company and BeFit Foods. HS has previously received non-financial and financial support from CD investments VSL pharmaceuticals and is currently funded by an Alfred Deakin Postdoctoral Research Fellowship. FNJ is supported by an NHMRC Investigator Grant (#1194982). She has received the following funding: (1) competitive Grant/Research support from the Brain and Behaviour Research Institute, the National Health and Medical Research Council (NHMRC), Australian Rotary Health, the Geelong Medical Research Foundation, the Ian Potter Foundation, The University of Melbourne; (2) industry support for research from Meat and Livestock Australia, Woolworths Limited, the A2 Milk Company, BeFit Foods; (3) philanthropic support from the Fernwood Foundation, Wilson Foundation, the JTM Foundation, the Serp Hills Foundation, the Roberts Family Foundation, the Waterloo Foundation; and (4) travel support and speakers honoraria from Sanofi-Synthelabo, Janssen Cilag, Servier, Pfizer, Network Nutrition, Angelini Farmaceutica, Eli Lilly, Metagenics and The Beauty Chef. FNJ has written two books for commercial publication.

Author information

Authors and Affiliations

Authors

Contributions

WM and FNJ drafted the manuscript. All authors provided feedback on the draft and approved of the final manuscript.

Corresponding author

Correspondence to Wolfgang Marx.

Ethics declarations

Competing interest

KW, ST, AS-V, HA and TA declare no competing interests.

Additional information

Publisher’s note Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Marx, W., Lane, M.M., Hockey, M. et al. Diet and depression: future needs to unlock the potential. Mol Psychiatry 27, 778–780 (2022). https://doi.org/10.1038/s41380-021-01360-2

Download citation

  • Received:

  • Revised:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1038/s41380-021-01360-2

Search

Quick links